Background Atrial fibrillation (AF) poses a significant stroke risk in heart disease patients.
This systematic review aims to evaluate the efficacy and safety of non-vitamin K oral …

Non-vitamin K antagonist oral anticoagulants (NOACs) are a new class of anticoagulant
drugs used in the prevention and treatment of venous thromboembolism (VTE) and atrial …

Aim: The aim of our study was to investigate whether preclinical and clinical studies
published in medical journals of Bosnia and Herzegovina satisfy basic requirements for …

Abstract Background Oral anticoagulants (OACs) are high-risk medications often used in
older people with complex medication regimens. This study was the first to assess the …

Non–vitamin K antagonist oral anticoagulants (NOACs) are a widely prescribed treatment to
prevent stroke in patients with nonvalvular atrial fibrillation, and a therapy and preventative …

Introduction Treatment adherence and persistence impact the effectiveness of edoxaban for
the prevention of thromboembolism in patients with atrial fibrillation (AF). The objective of …

Nonvalvular atrial fibrillation (NVAF) is associated with an increased risk of stroke and
thrombus, and anticoagulant therapy is a key link in the prevention of stroke. At present, the …

Aims Direct oral anticoagulant (DOAC) is widely used for the prevention of embolic stroke in
non-valvular atrial fibrillation (NVAF) patients. However, the gastrointestinal bleeding risk in …

Cancer-associated thrombosis (CAT) is a common complication of malignancies. Patients
with CAT are at risk of venous thromboembolism recurrence, but also at risk of bleeding …

Four direct oral anticoagulants (DOACs) are used in Japan (edoxaban, rivaroxaban,
apixaban, and dabigatran); however, few studies have examined the long‐term treatment …